5 Best Up and Coming Stocks with Highest Upside Potential

4. Nuvalent (NASDAQ:NUVL)

Average Upside Potential: 41.11%

Nuvalent (NASDAQ:NUVL) is one of the best up and coming stocks with highest upside potential. On April 7, Nuvalent submitted an NDA to the FDA for neladalkib, its investigational ALK-selective inhibitor for patients with advanced ALK-positive non-small cell lung cancer/NSCLC who have previously been treated with tyrosine kinase inhibitors/TKIs. This submission comes less than four years after the initiation of the first clinical trial, reflecting an accelerated development timeline supported by the FDA’s Breakthrough Therapy Designation.

The application is supported by data from the ALKOVE-1 Phase 1/2 clinical trial. In pre-treated patients, neladalkib showed robust anti-tumor activity, including responses in patients with brain metastases. Crucially, the drug’s “ALK-selective, TRK-sparing” design aims to overcome resistance mutations (such as G1202R) caused by earlier-generation inhibitors while avoiding the neurological side effects often associated with off-target TRK inhibition.

Neladalkib is designed to be highly brain-penetrant, addressing a significant clinical need for patients whose cancer has spread to the central nervous system. Nuvalent (NASDAQ:NUVL) continues to enroll participants in the ALKOVE-1 study for other ALK-positive solid tumors and plans to present detailed results from the NSCLC cohort at an upcoming medical meeting.

Nuvalent (NASDAQ:NUVL) is a clinical-stage biopharmaceutical company that develops precisely targeted small molecule therapies for cancer. By using structure-based drug design, the firm creates innovative treatments for kinase targets designed to overcome resistance, address brain metastases, and minimize adverse effects.